查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1983140

週期性发烧（PF）市场：按疾病类型、治疗类型、给药途径、诊断类型、病患小组、最终用户、分销管道和地区划分。

Periodic Fever Market, By Disease Type, By Treatment Type, By Route of Administration, By Diagnosis Type, By Patient Group, By End User, By Distribution Channel, By Geography
出版日期: | 出版商: Coherent Market Insights | 英文 152 Pages | 商品交期: 2-3个工作天内

价格
简介目录

预计到 2026 年，週期性发热 (PF) 市场价值为 7.246 亿美元，到 2033 年将达到 10.0607 亿美元。预计从 2026 年到 2033 年，其复合年增长率将达到 4.8%。

报告范围 报告详情
基准年： 2025 2026年市场规模： 7.246亿美元
历史数据时期： 2020年至2024年 预测期： 2026年至2033年
2026年至2033年预测期间的复合年增长率： 4.80% 2033年市场规模预测： 1,006,070,000 美元

全球週期性发烧（PF）市场是罕见疾病治疗领域的一个专门细分市场，专注于以反覆发烧和发炎为特征的遗传性自体发炎症候群。这些疾病遗传性地中海热（FMF）、肿瘤坏死因子受体相关週期性症候群（TRAPS）和冷吡啉相关週期性症候群（CAPS），是一组影响全球数千名患者的遗传性疾病。

近年来，在诊断能力的提升、对疾病病理病理学认识的加深以及标靶治疗的开发等推动下，该市场取得了显着进展。製药和生技公司正加大研发投入，以满足该患者族群中尚未充分满足的庞大需求。

该市场涵盖多种旨在预防或减轻週期性发烧（PF）发作频率和严重程度的治疗方法，例如抗发炎药物、生物製药和新型标靶治疗。随着医疗专业人员意识的提高和诊断技术的进步，越来越多的患者能够获得准确的诊断和适当的治疗，从而推动市场稳定成长。最终，这将改善这些饱受自身发炎性疾病折磨的患者的生活品质。

市场动态

全球週期性发热（PF）市场主要受多种强劲因素驱动，这些因素持续影响其成长轨迹和市场渗透率。遗传性自体发炎症候群在全球的盛行率不断上升以及人们对这些疾病的认识不断提高，是推动市场成长要素。这是因为先进的基因检测和生物标记识别技术使医疗系统能够更精准地诊断这些以往未被充分认识的疾病。标靶生物製药和精准医疗方法的开发正在革新治疗模式，为患者提供更有效、安全性更高的治疗选择，优于传统的抗发炎疗法。

政府对孤儿药研发的扶持政策和监管支持，包括加速核准流程和市场独占奖励，鼓励製药公司投资于此细分治疗领域。然而，市场也存在着许多限制因素。特别是生物製药疗法的高昂成本，对病患和医疗系统构成了取得药物的障碍，尤其是在开发中国家。基层医疗医师对罕见疾病的认知不足，常导致诊断延误，延长病患的痛苦。同时，罕见疾病患者数量少，也为寻求投资回报的製药公司带来了商业性挑战。

这些遗传性疾病临床表现的复杂性和多样性为诊断和治疗带来了更大的挑战。然而，随着全球医疗基础设施的扩展、新兴市场医疗支出的成长以及製药业对罕见疾病药物组合的日益关注，也蕴藏着巨大的机会。联合治疗、基于基因谱分析的个人化治疗方案以及疗效更佳、副作用更小的新一代疗法的研发，都代表着巨大的市场拓展机会，有望彻底改变患者的治疗结果和市场动态。

本次调查的主要特点。

  • 本报告对全球週期性热能（PF）市场进行了详细分析，以 2025 年为基准年，给出了预测期（2026-2033 年）的市场规模和復合年增长率（%）。
  • 该报告揭示了各个细分市场的潜在商机，并说明了该市场中一系列有吸引力的投资提案。
  • 此外，本研究还提供了有关市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域展望以及主要企业采取的竞争策略的重要见解。
  • 本报告根据以下参数对全球週期性热（PF）市场的主要参与者进行了分析：公司概况、产品系列、主要亮点、财务表现和策略。
  • 透过利用本报告中提出的见解，企业行销负责人和经营团队将能够就未来的产品发布、产品升级、市场扩张和行销策略做出明智的决策。
  • 本报告面向该产业的各类相关人员，包括投资者、供应商、产品製造商、经销商、新参与企业和金融分析师。
  • 透过分析全球週期性热（PF）市场中使用的各种策略矩阵，相关人员将能够更轻鬆地做出决策。

目录

第一章：研究目标与前提条件

  • 研究目标
  • 前提
  • 简称

第二章 市场范围

  • 报告摘要
    • 市场定义和范围
  • 执行摘要

第三章：市场动态、监管与趋势分析

  • 市场动态
  • 影响分析
  • 主要亮点
  • 法规环境
  • 产品上市及核准
  • PEST分析
  • 波特的分析
  • 市场机会
  • 法规环境
  • 主要进展
  • 产业趋势

第四章 全球週期性发烧（PF）市场：依疾病类型划分，2021-2033年

  • 遗传性地中海热
  • TNF受体相关週期性综合症
  • 甲羟戊酸激酶缺乏症
  • 冷吡啉相关週期性综合症
  • PFAPA症候群
  • 系统性自体发炎性週期性发热

第五章 全球週期性发烧（PF）市场：依治疗类型划分，2021-2033年

  • 生物製药
  • 皮质类固醇
  • 秋水仙碱疗法
  • 非类固醇抗发炎药和症状治疗
  • 免疫抑制剂
  • 新兴的标靶治疗和基因疗法

第六章 全球週期性发烧（PF）市场：依给药途径划分，2021-2033年

  • 注射
  • 口服
  • 静脉注射

第七章 全球週期性发热（PF）市场：依诊断类型划分，2021-2033年

  • 基因检测
  • 检测和生物标记检测
  • 临床诊断
  • 诊断影像和辅助诊断方法

第八章 全球週期性发烧（PF）市场：依病患小组，2021-2033年

  • 儿童患者
  • 成年患者

第九章 全球週期性热（PF）市场：依最终用户划分，2021-2033年

  • 医院
  • 风湿病专科诊所
  • 门诊手术中心
  • 居家医疗

第十章 全球週期性热（PF）市场：依通路划分，2021-2033年

  • 在线的
  • 离线

第十一章 全球週期性发热（PF）市场：按地区划分，2021-2033年

  • 北美洲
    • 我们
    • 加拿大
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 墨西哥
    • 其他拉丁美洲
  • 欧洲
    • 德国
    • 英国
    • 西班牙
    • 法国
    • 义大利
    • 俄罗斯
    • 其他欧洲国家
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳洲
    • 韩国
    • ASEAN
    • 亚太其他地区
  • 中东
    • 海湾合作委员会国家
    • 以色列
    • 其他中东国家
  • 非洲
    • 南非
    • 北非
    • 中非

第十二章 竞争格局

  • Novartis
  • Swedish Orphan Biovitrum Sobi
  • Regeneron Pharmaceuticals
  • Takeda Pharmaceutical Company
  • Hikma Pharmaceuticals
  • Amgen
  • Pfizer
  • AbbVie
  • Janssen Biotech Johnson and Johnson
  • Roche
  • Sanofi
  • UCB
  • Bristol Myers Squibb
  • Teva Pharmaceutical Industries
  • Dr Reddys Laboratories

第十三章 分析师建议

  • 机会
  • 分析师意见
  • Coherent Opportunity Map

第十四章 参考文献与调查方法

  • 参考
  • 调查方法
  • 关于本公司
简介目录
Product Code: CMI9297

Periodic Fever Market is estimated to be valued at USD 724.6 Mn in 2026 and is expected to reach USD 1,006.07 Mn by 2033, growing at a compound annual growth rate (CAGR) of 4.8% from 2026 to 2033.

Report Coverage Report Details
Base Year: 2025 Market Size in 2026: USD 724.6 Mn
Historical Data for: 2020 To 2024 Forecast Period: 2026 To 2033
Forecast Period 2026 to 2033 CAGR: 4.80% 2033 Value Projection: USD 1,006.07 Mn

The global periodic fever market encompasses a specialized segment of the rare disease therapeutics landscape, focusing on hereditary autoinflammatory syndromes characterized by recurrent episodes of fever and inflammation. These conditions, including Familial Mediterranean Fever (FMF), Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS), and Cryopyrin-Associated Periodic Syndromes (CAPS), represent a group of genetically inherited disorders affecting thousands of patients worldwide.

The market has witnessed significant advancement in recent years, driven by enhanced diagnostic capabilities, improved understanding of disease pathophysiology, and the development of targeted therapeutic interventions. Pharmaceutical companies and biotechnology firms are increasingly investing in research and development activities to address the substantial unmet medical needs within this patient population.

The market encompasses various treatment modalities, including anti-inflammatory agents, biologics, and novel targeted therapies designed to prevent or reduce the frequency and severity of periodic fever episodes. With growing awareness among healthcare professionals and improved diagnostic techniques, the market is experiencing steady expansion as more patients receive accurate diagnoses and appropriate treatment interventions, ultimately improving quality of life outcomes for individuals suffering from these debilitating autoinflammatory conditions.

Market Dynamics

The global periodic fever market is primarily driven by several compelling factors that continue to shape its growth trajectory and market penetration. The increasing prevalence and recognition of hereditary autoinflammatory syndromes worldwide serves as a fundamental growth driver, as healthcare systems become more sophisticated in diagnosing these previously under-recognized conditions through advanced genetic testing and biomarker identification technologies. The development of targeted biologics and precision medicine approaches has revolutionized treatment paradigms, offering patients more effective therapeutic options with improved safety profiles compared to traditional anti-inflammatory treatments.

Government initiatives and regulatory support for orphan drug development, including expedited approval pathways and market exclusivity incentives, have encouraged pharmaceutical investments in this niche therapeutic area. However, the market faces significant restraints including the extremely high costs associated with biologic therapies, which create accessibility barriers for patients and healthcare systems, particularly in developing economies. Limited disease awareness among primary care physicians often leads to delayed diagnoses and prolonged patient suffering, while the small patient populations inherent to rare diseases present commercial challenges for pharmaceutical companies seeking return on investment.

The complexity of these genetic disorders and variability in clinical presentations create additional diagnostic and treatment challenges. Nevertheless, substantial opportunities exist through expanding global healthcare infrastructure, increasing healthcare expenditure in emerging markets, and growing pharmaceutical industry focus on rare disease portfolios. The potential for combination therapies, personalized treatment approaches based on genetic profiling, and the development of next-generation therapeutics with improved efficacy and reduced side effect profiles represent significant market expansion opportunities that could transform patient outcomes and market dynamics.

Key Features of the Study

  • This report provides in-depth analysis of the global Periodic Fever market, and provides market size (USD Mn) and compound annual growth rate (CAGR%) for the forecast period (2026-2033), considering 2025 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global periodic fever market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include Novartis, Swedish Orphan Biovitrum Sobi, Regeneron Pharmaceuticals, Takeda Pharmaceutical Company, Hikma Pharmaceuticals, Amgen, Pfizer, AbbVie, Janssen Biotech Johnson and Johnson, Roche, Sanofi, UCB, Bristol Myers Squibb, Teva Pharmaceutical Industries, and Dr Reddys Laboratories
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global periodic fever market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global periodic fever market

Market Segmentation

  • Disease Type Insights (Revenue, USD Mn, 2021 - 2033)
    • Familial Mediterranean Fever
    • TNF Receptor-Associated Periodic Syndrome
    • Mevalonate Kinase Deficiency
    • Cryopyrin-Associated Periodic Syndromes
    • PFAPA Syndrome
    • Systemic Autoinflammatory Periodic Fevers
  • Treatment Type Insights (Revenue, USD Mn, 2021 - 2033)
    • Biologic Therapies
    • Corticosteroids
    • Colchicine Therapy
    • NSAIDs & Symptomatic Treatments
    • Immunosuppressants
    • Emerging Targeted Therapies & Gene-based Treatments
  • Route of Administration Insights (Revenue, USD Mn, 2021 - 2033)
    • Injectable
    • Oral
    • Intravenous Infusion
  • Diagnosis Type Insights (Revenue, USD Mn, 2021 - 2033)
    • Genetic Testing
    • Laboratory & Biomarker Testing
    • Clinical Diagnosis
    • Imaging & Supportive Diagnostic Methods
  • Patient Group Insights (Revenue, USD Mn, 2021 - 2033)
    • Pediatric Patients
    • Adult Patients
  • End User Insights (Revenue, USD Mn, 2021 - 2033)
    • Hospitals
    • Specialty & Rheumatology Clinics
    • Ambulatory Surgical Centers
    • Homecare Settings
  • Distribution Channel Insights (Revenue, USD Mn, 2021 - 2033)
    • Online
    • Offline
  • Regional Insights (Revenue, USD Mn, 2021 - 2033)
    • North America
    • U.S.
    • Canada
    • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
    • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
    • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
    • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
    • Africa
    • South Africa
    • North Africa
    • Central Africa
  • Key Players Insights
    • Novartis
    • Swedish Orphan Biovitrum Sobi
    • Regeneron Pharmaceuticals
    • Takeda Pharmaceutical Company
    • Hikma Pharmaceuticals
    • Amgen
    • Pfizer
    • AbbVie
    • Janssen Biotech Johnson and Johnson
    • Roche
    • Sanofi
    • UCB
    • Bristol Myers Squibb
    • Teva Pharmaceutical Industries
    • Dr Reddys Laboratories

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Global Periodic Fever Market, By Disease Type
    • Global Periodic Fever Market, By Treatment Type
    • Global Periodic Fever Market, By Route of Administration
    • Global Periodic Fever Market, By Diagnosis Type
    • Global Periodic Fever Market, By Patient Group
    • Global Periodic Fever Market, By End User
    • Global Periodic Fever Market, By Distribution Channel
    • Global Periodic Fever Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
  • Impact Analysis
  • Key Highlights
  • Regulatory Scenario
  • Product Launches/Approvals
  • PEST Analysis
  • PORTER's Analysis
  • Market Opportunities
  • Regulatory Scenario
  • Key Developments
  • Industry Trends

4. Global Periodic Fever Market, By Disease Type, 2021-2033, (USD Mn)

  • Introduction
    • Market Share Analysis, 2026 and 2033 (%)
    • Y-o-Y Growth Analysis, 2022 - 2033
    • Segment Trends
  • Familial Mediterranean Fever
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
  • TNF Receptor-Associated Periodic Syndrome
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
  • Mevalonate Kinase Deficiency
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
  • Cryopyrin-Associated Periodic Syndromes
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
  • PFAPA Syndrome
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
  • Systemic Autoinflammatory Periodic Fevers
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)

5. Global Periodic Fever Market, By Treatment Type, 2021-2033, (USD Mn)

  • Introduction
    • Market Share Analysis, 2026 and 2033 (%)
    • Y-o-Y Growth Analysis, 2022 - 2033
    • Segment Trends
  • Biologic Therapies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
  • Corticosteroids
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
  • Colchicine Therapy
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
  • NSAIDs & Symptomatic Treatments
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
  • Immunosuppressants
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
  • Emerging Targeted Therapies & Gene-based Treatments
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)

6. Global Periodic Fever Market, By Route of Administration, 2021-2033, (USD Mn)

  • Introduction
    • Market Share Analysis, 2026 and 2033 (%)
    • Y-o-Y Growth Analysis, 2022 - 2033
    • Segment Trends
  • Injectable
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
  • Oral
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
  • Intravenous Infusion
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)

7. Global Periodic Fever Market, By Diagnosis Type, 2021-2033, (USD Mn)

  • Introduction
    • Market Share Analysis, 2026 and 2033 (%)
    • Y-o-Y Growth Analysis, 2022 - 2033
    • Segment Trends
  • Genetic Testing
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
  • Laboratory & Biomarker Testing
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
  • Clinical Diagnosis
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
  • Imaging & Supportive Diagnostic Methods
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)

8. Global Periodic Fever Market, By Patient Group, 2021-2033, (USD Mn)

  • Introduction
    • Market Share Analysis, 2026 and 2033 (%)
    • Y-o-Y Growth Analysis, 2022 - 2033
    • Segment Trends
  • Pediatric Patients
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
  • Adult Patients
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)

9. Global Periodic Fever Market, By End User, 2021-2033, (USD Mn)

  • Introduction
    • Market Share Analysis, 2026 and 2033 (%)
    • Y-o-Y Growth Analysis, 2022 - 2033
    • Segment Trends
  • Hospitals
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
  • Specialty & Rheumatology Clinics
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
  • Ambulatory Surgical Centers
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
  • Homecare Settings
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)

10. Global Periodic Fever Market, By Distribution Channel, 2021-2033, (USD Mn)

  • Introduction
    • Market Share Analysis, 2026 and 2033 (%)
    • Y-o-Y Growth Analysis, 2022 - 2033
    • Segment Trends
  • Online
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
  • Offline
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)

11. Global Periodic Fever Market, By Region, 2021 - 2033, Value (USD Mn)

  • Introduction
    • Market Share (%) Analysis, 2026, 2029 & 2033, Value (USD Mn)
    • Market Y-o-Y Growth Analysis (%), 2022 - 2033, Value (USD Mn)
    • Regional Trends
  • North America
    • Introduction
    • Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Mn)
    • Market Size and Forecast, By Treatment Type, 2021 - 2033, Value (USD Mn)
    • Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Mn)
    • Market Size and Forecast, By Diagnosis Type, 2021 - 2033, Value (USD Mn)
    • Market Size and Forecast, By Patient Group, 2021 - 2033, Value (USD Mn)
    • Market Size and Forecast, By End User, 2021 - 2033, Value (USD Mn)
    • Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)
    • Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
      • U.S.
      • Canada
  • Latin America
    • Introduction
    • Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Mn)
    • Market Size and Forecast, By Treatment Type, 2021 - 2033, Value (USD Mn)
    • Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Mn)
    • Market Size and Forecast, By Diagnosis Type, 2021 - 2033, Value (USD Mn)
    • Market Size and Forecast, By Patient Group, 2021 - 2033, Value (USD Mn)
    • Market Size and Forecast, By End User, 2021 - 2033, Value (USD Mn)
    • Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)
    • Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
      • Brazil
      • Argentina
      • Mexico
      • Rest of Latin America
  • Europe
    • Introduction
    • Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Mn)
    • Market Size and Forecast, By Treatment Type, 2021 - 2033, Value (USD Mn)
    • Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Mn)
    • Market Size and Forecast, By Diagnosis Type, 2021 - 2033, Value (USD Mn)
    • Market Size and Forecast, By Patient Group, 2021 - 2033, Value (USD Mn)
    • Market Size and Forecast, By End User, 2021 - 2033, Value (USD Mn)
    • Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)
    • Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
      • Germany
      • U.K.
      • Spain
      • France
      • Italy
      • Russia
      • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Mn)
    • Market Size and Forecast, By Treatment Type, 2021 - 2033, Value (USD Mn)
    • Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Mn)
    • Market Size and Forecast, By Diagnosis Type, 2021 - 2033, Value (USD Mn)
    • Market Size and Forecast, By Patient Group, 2021 - 2033, Value (USD Mn)
    • Market Size and Forecast, By End User, 2021 - 2033, Value (USD Mn)
    • Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)
    • Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
  • Middle East
    • Introduction
    • Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Mn)
    • Market Size and Forecast, By Treatment Type, 2021 - 2033, Value (USD Mn)
    • Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Mn)
    • Market Size and Forecast, By Diagnosis Type, 2021 - 2033, Value (USD Mn)
    • Market Size and Forecast, By Patient Group, 2021 - 2033, Value (USD Mn)
    • Market Size and Forecast, By End User, 2021 - 2033, Value (USD Mn)
    • Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)
    • Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
      • GCC Countries
      • Israel
      • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Mn)
    • Market Size and Forecast, By Treatment Type, 2021 - 2033, Value (USD Mn)
    • Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Mn)
    • Market Size and Forecast, By Diagnosis Type, 2021 - 2033, Value (USD Mn)
    • Market Size and Forecast, By Patient Group, 2021 - 2033, Value (USD Mn)
    • Market Size and Forecast, By End User, 2021 - 2033, Value (USD Mn)
    • Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)
    • Market Size and Forecast, By Country/Region, 2021 - 2033, Value (USD Mn)
      • South Africa
      • North Africa
      • Central Africa

12. Competitive Landscape

  • Novartis
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Swedish Orphan Biovitrum Sobi
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Regeneron Pharmaceuticals
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Takeda Pharmaceutical Company
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Hikma Pharmaceuticals
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Amgen
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Pfizer
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • AbbVie
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Janssen Biotech Johnson and Johnson
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Roche
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Sanofi
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • UCB
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Bristol Myers Squibb
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Teva Pharmaceutical Industries
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Dr Reddys Laboratories
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies

13. Analyst Recommendations

  • Wheel of Fortune
  • Analyst View
  • Coherent Opportunity Map

14. References and Research Methodology

  • References
  • Research Methodology
  • About us